Table 1 Patient demographics of the 281 enrolled patients
Characteristics | Number of patients (%) |
|---|---|
Age (years) | 38 (16–75) |
Sex | |
Male:Female | 85 (30.2%):196 (69.8%) |
Thyroid gland weight (g) | 19.0 (4.2–127.0) |
Primary tumor size (cm) | 1.3 (0.3–7.0) |
Pathologic TNM stage | |
T1aN1b | 25 (8.9%) |
T1bN1b | 10 (3.6%) |
T2N1b | 5 (1.8%) |
T3N0 | 2 (0.7%) |
T3N1a | 8 (2.8%) |
T3N1b | 231 (82.2%) |
ATA risk stratification | |
Intermediate risk | 196 (69.8%) |
High risk | 85 (30.2%) |
Assay at ablation | |
TSH (mIU/mL) | 51.31 (30.13–158.81) |
Tg (ng/mL) | 2.5 (0.039–280.0) |
TgAb (IU/mL) | 10.9 (9.9–1,859.0) |
I-131 WBS analysis | |
Early WBS neck counta | 49,823 (656–560,227) |
Delayed WBS neck counta | 2,379 (85–46,212) |
Reduction ratio (%) | 95.2 (70.1–99.3) |
Interval between surgery and ablation (months) | 3.1 (1.5–8.5) |
Thyroiditis (Present:None) | 70 (24.9%):211 (75.1%) |
Ablation success: Ablation failure | 157 (55.9%):124 (44.1%) |